Skip to main content
. 2013 Jan 18;288(9):6542–6551. doi: 10.1074/jbc.M112.429084

FIGURE 5.

FIGURE 5.

GPR40 agonist as a protective agent against in vivo OVX-induced bone loss. A, bone microarchitecture (females; OVX, ovariectomy; Sh, Sham-operated; 14-week-old mice; n = 7 per group; BV/TV, bone volume/total volume; Tb.N, trabecular number; Tb.Sp, trabecular spaces; Tb.Th, trabecular thickness). Mice received either DMSO as vehicle or GPR40 agonist GW9508 (8 mg/kg of body weight: GW). B, representative bone tissue marker expression analyzed by TLDA on whole tibiae (Applied Biosystems 7900HT real-time PCR system). Tissues were collected from OVX or Sham-operated mice that received either DMSO as vehicle or GPR40 agonist GW9508 (8 mg/kg of body weight: GW). Different letters are attributed to significantly different groups (p < 0.05); error bars represent standard deviation (±S.D.).